Arch dimensional changes in children with idiopathic short stature treated with recombinant growth hormone: a five-year study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Dental casts of 28 short subjects (22 male, 6 female) and of age/gender-matched controls of normal stature were analyzed using a digital imaging system.

Four measures of arch width and one of arch depth were calculated for each maxillary and mandibular cast.

Who Took Part

The study group was 28 subjects.

The age groups tagged for this paper are young children, children and teenagers, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Four measures of arch width and one of arch depth were calculated for each maxillary and mandibular cast.

Z-scores were calculated to allow for pooling of data.

Topics PubMed links to this paper include Body Height, Case-Control Studies, Cephalometry, Dental Arch, Growth Disorders, Growth Hormone and Image Processing, Computer-Assisted.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 28 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1995 (The Angle orthodontist), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.